Phoenix Biotech Acquisition Corp. Unit
PBAXU
PBAXU was delisted on the 7th of February, 2024.
37 hedge funds and large institutions have $65.5M invested in Phoenix Biotech Acquisition Corp. Unit in 2021 Q4 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$7.59M |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$6.07M |
| 3 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$5.06M |
| 4 |
LA
Linden Advisors
New York
|
+$5.06M |
| 5 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$5.06M |
Top Sellers
PBAXU Hedge Fund Activity: Q4 2021 in Review
37 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q4 2021, worth a combined $65.5M.
Buyers outnumbered sellers: 37 funds opened new PBAXU positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Shaolin Capital Management, opening a new position worth an estimated $7.59M.
- 37 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $65.5M of Phoenix Biotech Acquisition Corp. Unit stock for Q4 2021.
- 37 funds opened new Phoenix Biotech Acquisition Corp. Unit positions in Q4 2021 and 0 closed out, a net change of +37 holders.
- The largest Phoenix Biotech Acquisition Corp. Unit buyer in Q4 2021 was Shaolin Capital Management, an estimated $7.59M added.
Based on aggregated 13F filings for Q4 2021.